Cincinnati Center for Eosinophilic Disorders Research
Upcoming EGID Research

Upcoming EGID Research

Through the collaborative efforts of the Campaign Urging Research for Eosinophilic Diseases (CURED), Cincinnati Center for Eosinophilic Disorders (CCED) and the awards committee members, six winning abstracts were recognized at the 7th CURED EGID Conference and Patient Education Program (2024). Many of the >45 research abstracts were facilitated or generated by the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), with awardees presenting their findings as late-breaking discoveries. The two winning abstracts with contributions from the CCED are presented below. 

EGIDExpress: An Interactive Shiny Web App to Visualize and Share Large Biological Datasets

Garrett Osswald, BS,1 John Besse, MS,1 Marc E. Rothenberg, MD, PhD1

Background: Eosinophilic gastrointestinal diseases (EGIDs) are rare conditions associated with inappropriate inflammation and accumulation of eosinophils in segments of the gastrointestinal tract. We aimed to develop an online platform (EGIDExpress) to facilitate data sharing and hypothesis generation for large EGID-related datasets of all types.

Methods: EGIDExpress (https://egidexpress.research.cchmc.org) was developed using the R programming language and utilizes the R Shiny package for the graphical interface. Data such as expression matrices, Seurat objects, or files from any large biological experiment can be quickly integrated into the platform. EGIDExpress allows a user to rapidly filter, sort, or retrieve data, graphs, or statistics for each dataset. Each contains a link to the related publication and a short experimental description. Users can choose a gene, protein, or SNP from a dropdown menu to display relevant graphical and statistical data. Specific datasets allow a user to filter and sort displayed data with additional input fields. Additional tabs display tabular expression data, provide sample information, or allow users to download expression data for further analysis.

Results: Since launching in 2019, EGIDExpress has been a key tool for research within the laboratory and the field. It has generated interest from the public, academic collaborators, and industry partners. It has been accepted by journals as a qualifying online repository for data deposition. As of February 2024, the platform contains 24 datasets publicly available and 22 datasets on the private site. To date, there have been 3,132 visitors to the public site from 49 countries and 43 US states. EGIDExpress has been updated with an improved data management system and added capability for GWAS datasets in 2023. EGIDExpress provides a streamlined graphical interface for users to manipulate the data to quickly produce informative results. Results are presented in a format that is easily shareable for laboratory meetings or publications. Users can generate results for a gene, protein, or SNP of interest quickly across numerous datasets efficiently. Data integrity is maintained, as EGIDExpress is a read-only interface for the user.

Conclusions: EGIDExpress provides the ability to store, share, and analyze published data with the public and unpublished data within the laboratory and collaborators. It allows for new datasets and new experimental types to be added as the search for improved diagnostics and treatments, and a cure for EGIDs, continues.

Author Affiliations: Garrett.osswald@cchmc.org, John.besse@cchmc.org, Marc. Rothenberg@cchmc.org. 1Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 

Persistent Esophageal Changes Following Histologic Remission in Eosinophilic Esophagitis

Melanie A. Ruffner MD PhD,1,2*,# Tetsuo Shoda MD, PhD,3* Megha Lal PhD,2 Zoe Mrozek,2 Amanda B. Muir MD,1,4 Jonathan M. Spergel MD, PhD,1,2 Evan S. Dellon MD,5 Marc E. Rothenberg MD, PhD3

Background: Eosinophilic esophagitis (EoE) is characterized by persistent or relapsing allergic inflammation, and both clinical and histologic features of esophageal inflammation persist over time in most individuals. Mechanisms contributing to EoE relapse are not understood. Chronic EoE-directed therapy is required to prevent long-term fibrostenotic sequelae. In this study, we investigated whether patients with EoE in histologic remission have persistent dysregulation of esophageal gene expression.

Methods: Esophageal biopsies from pediatric (n = 51) and adult (n = 52) subjects with EoE in histopathologic remission (<15 eosinophils/high-power field [eos/HPF]) and control (n = 48 pediatric, n = 167 adult) subjects from multiple institutions were subjected to molecular profiling by the EoE Diagnostic Panel (EDP), a set of 94 esophageal transcripts differentially expressed in active EoE. 

Results: We identified 51 and 32 differentially expressed genes in pediatric and adult patients with EoE in remission (<15 eos/HPF) compared to control individuals, respectively (FDR < 0.05). Using the stringent definition of remission (0 eos/HPF), the adult and pediatric cohorts continued to have 18 and 25 differentially expressed genes (FDR < 0.05). Among 6 shared genes between adults and children, cadherin 26 (CDH26) was upregulated in both children and adults; immunohistochemistry demonstrated increased cadherin 26 staining in the epithelium of patients with EoE in remission compared to non-EoE controls. In the adult cohort, POSTN expression correlated with the Endoscopic Reference Score (Spearman r = 0.35, p = 0.011), specifically correlating with the rings EREFS subscore (r = 0.53, p = 0.004).

Conclusion: We have identified persistent EoE-associated esophageal gene expression in patients with deep remission. These data suggest potential inflammation-induced epigenetic mechanisms may influence gene expression during remission in EoE and provide insight into possible mechanisms that underlie relapse in EoE.

Author Affiliations: *Contributed equally. #ruffnerm@chop.edu. 1Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; 2Division of Allergy & Immunology, Children’s Hospital of Philadelphia, Philadelphia PA; 3Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio; 4Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia, Philadelphia PA; 5Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine

CURED Research Conference and Patient Education Program

Learn more about the CURED Research Conference and Patient Education Program and other Events and Educational Opportunities with the Cincinnati Center for Eosinophilic Disorders.

CURED

The Campaign Urging Research for Eosinophilic Diseases (CURED) is a nonprofit organization dedicated to raising funds to aid in research and public awareness of eosinophilic disorders. Learn more about CURED or how to get involved with its upcoming fundraising opportunities.

CEGIR

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations. CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN) and has a contact registry. Consider joining today. Read more